What a laboratory-only shipment has to carry, and who it may go to

A lane that is usually described as empty

The usual account of laboratory-only material is that it sits outside the drug rules entirely. That account is close but not right, and the gap matters.

The federal investigational drug rules contain a short section written for exactly this situation. It covers material shipped solely for tests in glassware or in animals kept for laboratory research.

It is not a license and it is not an approval. It is a set of conditions, and a companion section elsewhere in the same part makes the exemption depend on meeting them.

Reading the two together is worth a few minutes, because the conditions describe a transaction that looks very little like an online order.

Where the exemption comes from, and what it hangs on

The applicability section of the part states the general position first, and it is worth having in its own words. Its opening runs: "Except as provided in this section, this part applies to all clinical investigations of products". The sentence then names which products those are: those "subject to section 505 of the Federal Food, Drug, and Cosmetic Act or to the licensing provisions of the Public Health Service Act".

The exemptions then follow, and one of them is a single sentence. A drug intended solely for tests in glassware or in laboratory research animals is exempt from the requirements of the part if shipped in accordance with the laboratory shipment section.

Notice the grammar. The exemption is conditional, and the condition is a cross-reference to another section rather than a description of a product.

So the question is never whether a vial is labeled a certain way. The question is whether the shipment met a named set of conditions, and those conditions are printed in full.

The caution the section actually prescribes

The shipment section opens by authorizing a shipment and then fixing the words on it. A person may ship such a drug if it is labeled as follows.

The prescribed text reads: contains a new drug for investigational use only in laboratory research animals, or for tests in vitro. Not for use in humans.

Three things in that sentence do work. It calls the contents a new drug. It names the two permitted uses. It closes with a flat statement about people.

A separate paragraph covers a small family of diagnostic biological products, and the list is closed at three items: blood grouping serum, reagent red blood cells and anti-human globulin.

That closed list is a useful reminder of how narrow these doors are. An exemption written for three named reagents is not a general category for anything sold as a laboratory item.

The duty that has nothing to do with the label

The next paragraph is the one that rarely gets quoted, and it is the most interesting sentence in the section.

A person shipping a drug under that paragraph shall use due diligence to assure that the consignee is regularly engaged in conducting such tests. The same sentence adds that the shipment will actually be used for those tests.

That is a duty about the recipient rather than about the packaging. The shipper has to form a view, in advance, about who is on the other end and what they are going to do.

It is also a continuing standard rather than a checkbox. Due diligence and regularly engaged are both phrases that describe an ongoing state of affairs.

Set that beside an ordinary consumer checkout and the difference is not subtle. A cart and a card do not establish that a buyer is regularly engaged in conducting laboratory tests.

The record, and who may read it

A third paragraph turns the arrangement into paper. The shipper must maintain adequate records showing the name and post office address of the expert to whom the drug is shipped.

Each shipment and delivery also gets a date, a quantity and a batch or code mark. Those four items are the whole record, and they are named in the rule.

Records of shipments under the laboratory paragraph are kept for a period of two years after the shipment. The diagnostic biological products follow the sponsor recordkeeping rule instead.

The paragraph then opens the file. On request from any properly authorized officer or employee of the agency, at reasonable times, the shipper must permit access to copy and verify those records.

The word expert is worth pausing on. The rule does not describe the recipient as a customer or an account. It describes a person expected to be doing the tests.

How the arrangement gets switched off

The section has a second half, and it is about ending the permission rather than granting it.

The agency may terminate authorization to ship if it finds that the sponsor of the investigation has failed to comply with any of the conditions for shipment established under the section.

There is a second ground, and it is broader. Termination may follow if continuance of the investigation is unsafe or otherwise contrary to the public interest, or if the drug is used for purposes other than bona fide scientific investigation.

That last clause points at use rather than at paperwork. A shipment can satisfy every labeling and record condition and still fall outside the ground the rule describes.

The procedure is short. The agency notifies the shipper of its finding and invites immediate correction. If correction is not immediately made, the shipper has an opportunity for a regulatory hearing.

What happens to what is left over

The final paragraph deals with the drug that never got used, and it runs in the opposite direction from a normal sale.

The shipper must assure the return of all unused supplies of the drug from individual investigators whenever the investigation discontinues or is terminated.

An alternative is permitted, and it has to be in writing. The shipper may authorize alternative disposition provided that it does not expose humans to risks from the drug, either directly or indirectly.

The rule gives its own example of the indirect route, and it is food-producing animals. Records of any alternative disposition have to be maintained.

So the material is expected to come back or be accounted for. Nothing in the section contemplates a supply that simply stays wherever it was sent.

The scope, stated again because it decides the meaning

The applicability section says it plainly, and it is worth repeating exactly. Its first clause reads: "Except as provided in this section, this part applies to all clinical investigations of products". Its second names them: those "subject to section 505 of the Federal Food, Drug, and Cosmetic Act or to the licensing provisions of the Public Health Service Act".

The same section carves out one more thing at the end. The part does not apply to the use in the practice of medicine of an unlabeled indication of an approved drug product or a licensed biological product.

Read together, the part is addressed to investigations and to the people running them. It is not a general consumer protection rule and it does not read as one.

Whether a particular substance is a new drug, and whether a particular sale sits inside or outside this exemption, are legal questions that turn on specific facts. This site does not answer them, and a companion article holds the same line.

What a reader can take from a rule that may not apply

The value here is a set of comparisons, and every one of them is free to make.

The regulation prints a specific caution naming laboratory research animals and tests in glassware. A page can be read against that wording rather than against a general impression.

The regulation places a diligence duty on the shipper about who the recipient is. A checkout that asks nothing has answered that comparison by itself.

The regulation keeps a shipment record with a name, a date, a quantity and a batch mark, held for two years and open to the agency. That is a very different artifact from an order confirmation.

And the regulation expects unused material back, or accounted for in writing. A description of a laboratory supply lane that includes none of those features is describing something else.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. 21 CFR 312.160 — Drugs for investigational use in laboratory research animals or in vitro tests, prescribing the caution statement, the due diligence duty regarding the consignee, the two-year shipment records, the grounds for terminating authorization to ship, and the disposition of unused drug — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
2. 21 CFR 312.2 — Applicability, including the general applicability sentence, the exemption for a drug intended solely for tests in vitro or in laboratory research animals shipped in accordance with the laboratory shipment section, the closed list of three in vitro diagnostic biological products, and the unlabeled indication carve-out — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026